Journal News

How do diet and lipoprotein levels affect heart health

Seema Nath
Oct. 23, 2024

Cardiovascular diseases are among the leading causes of death globally, taking an estimated 17.9 million lives each year. An important risk factor of heart disease is an unhealthy diet leading to overweight and obesity, high blood pressure and increased levels of glucose and lipids in blood. Drugs that help manage body weight have clinical value but do not help prevent premature deaths. Hence, scientists seek ways to identify and treat individuals at higher risk of heart disease.

Low-density lipoprotein particles transport cholesterol, phospholipids, triglycerides and certain vitamins in blood plasma. A single LDL particle contains 3,000 to 6,000 fat molecules and a single apolipoprotein B molecule, a large protein (blue), building the surface with phospholipids and cholesterol molecules (orange).
selvanegra/iStock
Low-density lipoprotein particles transport cholesterol, phospholipids, triglycerides and certain vitamins in blood plasma. A single LDL particle contains 3,000 to 6,000 fat molecules and a single apolipoprotein B molecule, a large protein (blue), building the surface with phospholipids and cholesterol molecules (orange).

Increased levels of triglycerides and small low-density lipoproteins, or LDL, and low level of high-density lipoproteins, or HDL are markers of atherogenic dyslipidemia, a metabolic condition that builds plaques in the arteries, leading to heart diseases. Previously, cross-sectional studies have shown a correlation between high triglyceride levels and soluble LDL receptor, or sLDLR.

Ronald Krauss and his group at the University of California, San Francisco in collaboration with Christopher Gardner’s team in Stanford University recently showed dynamic changes in lipids and lipoproteins in conjunction with sLDLR; the study was published in the Journal of Lipid Research.

Krauss is interested in understanding the mechanisms regulating plasma lipoprotein metabolism that may impact cardiovascular disease risk and discovering sLDLR as an important component that impacts it. The Krauss lab uses ion mobility analysis to subdivide fractions of various densities of lipoproteins into narrow intervals of their respective subclasses. His team used this technique to study the correlation between lipoprotein particles and cardiometabolic risk, a lipid measure of heart disease risk.

Gardner provided samples from Diet Intervention Examining the Factors Interacting with Treatment Success, or DIETFITS, a study in which people were given either a healthy low-fat or low-carbohydrate diet to determine how lipid and lipoprotein fractions influence cardiometabolic risk. The researchers investigated the cross-sectional and longitudinal relationship of lipids, lipoproteins related to the level of sLDLR and triglyceride with a baseline of six months.

According to Krauss, using principal component analysis, his team showed that the level of sLDLR is tightly regulated to these other lipid measurements. The study population was limited, so this study must be replicated to make generalizations about the conclusions.

It has already been shown that he protease, membrane type 1–matrix metalloproteinase, or MT1-MMP, cleaves the ligand binding domain of sLDLR capable of binding to very low-density lipoprotein, or VLDL, and LDL particle and increases the level of sLDLR in plasma.

“The work is clinically and scientifically important for developing new therapeutic approaches to either target the protease and/or other mechanisms to inhibit the cleaving of LDLR,” Krauss said. “As the free domain of LDLR circulating in plasma acquires new function by binding to VLDL, mechanisms to directly stop the association of LDLR with VLDL could also be potential measurement to lower the atherogenic dyslipidemia.”

Krauss said the study opens new avenues to explore “how the soluble LDLR achieves this new feature by unknown conformational changes.”

“MT1-MMP is thought to be activated by unknown inflammatory signaling pathways,” he said, “which also needs further investigation along with its mode of interaction with sLDLR.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Seema Nath

Seema Nath is a postdoctoral research fellow at the University of Texas Health Science Center at San Antonio. She is an ASBMB volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.

Pathogen-derived enzyme engineered for antibiotic design
Journal News

Pathogen-derived enzyme engineered for antibiotic design

Aug. 6, 2025

Engineered variants of a bacterial enzyme developed at the University at Buffalo accept larger substrates, paving the way for new acinetobactin-based antimicrobials. Read more about this recent JBC paper.